Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol. 14, Issue 5s (2025)
https://www.jneonatalsurg.com

OPEN ACCESS

A Survey on Artificial Intelligence-Powered Drug Discovery and Development in Real-Life Environments Including Neonatal Therapeutics

Jaswinder Singh[*1], Gaurav Dhiman[2]

[*1]Department of the AIML-CSE Apex Institute of Technology, Chandigarh University, Mohali, India

[2]University Centre for Research and Development, Chandigarh University, Mohali, India

Email ID: gdhiman0001@gmail.com

***Corresponding Author:**

Email ID: jaswinder.e15978@cumail.in, Email ID: jassi724@gmail.com

Cite this paper as: Jaswinder Singh, Gaurav Dhiman, (2025) A Survey on Artificial Intelligence-Powered Drug Discovery and Development in Real-Life Environments Including Neonatal Therapeutics. *Journal of Neonatal Surgery*, 14 (5s), 809-819.

ABSTRACT

The drug discovery and development process is a complex, time-consuming, and expensive endeavor, often taking over a decade and costing billions of dollars. Artificial Intelligence (AI) has emerged as a transformative tool in this domain, offering the potential to accelerate drug discovery, reduce costs, and improve success rates. This paper provides a comprehensive survey of AI-powered approaches in drug discovery and development, focusing on their real-life applications, challenges, and future directions. We explore how AI is being used in target identification, molecular design, clinical trials, and post-market surveillance, with **special attention to neonatal drug development**, where AI-driven models can aid in formulating safe, effective, and personalized treatments for newborns. The paper discusses the ethical, regulatory, and technical challenges that must be addressed for widespread adoption, particularly in the **development of neonatal-specific therapeutics** where precision and safety are critical. Additionally, we highlight case studies, emerging trends, and the integration of AI into real-world pharmaceutical workflows, emphasizing its role in improving drug repurposing, optimizing dosage formulations, and accelerating approval processes. By examining AI's impact on both general and **neonatal drug discovery**, this survey serves as a valuable resource for researchers, clinicians, and pharmaceutical experts aiming to leverage AI for next-generation therapeutics.

Keywords: *Neonatal Surgery; Healthcare; Artificial Intelligence; Machine-learning; Deep-learning.*

1. INTRODUCTION

The process of drug discovery is a cornerstone of modern healthcare, as it enables the development of new medications that improve health outcomes and alleviate the suffering caused by diseases. However, the path from a basic scientific discovery to an effective and approved therapeutic agent is long, arduous, and often fraught with high costs and failures. Drug discovery typically involves several stages, including target identification, compound screening, lead optimization, preclinical studies, clinical trials, and regulatory approval. Despite advances in pharmaceutical research, the average time for bringing a drug from the laboratory bench to the market remains approximately 10 to 15 years, with costs often exceeding $2 billion per successful drug. The high attrition rates and long timelines associated with traditional drug discovery have created an urgent need for innovation to address these limitations and make the process faster, more efficient, and less costly [1][2][3][4][5][6][7][8][9][10].

In this context, Artificial Intelligence (AI) has emerged as a transformative tool that is reshaping drug discovery and development. AI encompasses a range of computational techniques that enable systems to learn from data, recognize patterns, and make predictions without explicit programming. Machine Learning (ML), a subset of AI, has gained significant attention for its ability to analyze large datasets, uncover hidden insights, and provide predictions in complex, data-intensive domains. In drug discovery, AI models are increasingly being used to enhance various stages of the process, from early-stage drug design to clinical trial optimization, thus improving the success rate of therapeutic development [11][12][13][14][15][16].

AI technologies, including machine learning, deep learning, natural language processing (NLP), and reinforcement learning, offer numerous advantages in drug discovery. They can process vast amounts of biological and chemical data that would be

impossible for human researchers to analyze manually, identify correlations and patterns that might otherwise be missed, and predict the biological activity of novel compounds. AI models have demonstrated significant success in drug target identification, virtual screening, de novo drug design, predicting drug efficacy, and evaluating the safety of new drug candidates. These capabilities have the potential to revolutionize the pharmaceutical industry by reducing the time and costs required to develop new drugs, while also increasing the likelihood of discovering more effective therapies for a wide range of diseases [17][18][19][20][21][22][23][24][25].

In recent years, AI-powered drug discovery has seen considerable progress. Early-stage applications of AI, such as virtual screening of compounds using machine learning models, have already demonstrated significant efficiency gains compared to traditional methods. AI is also being used to optimize drug candidates through predictive models that can assess how a drug interacts with the body, its pharmacokinetics, and its potential side effects. These AI systems can simulate the interactions between drugs and their target proteins, allowing researchers to predict the efficacy of new compounds before they are even synthesized in the lab [26][27][28][29][30][31][32][33].

Moreover, AI-driven approaches have proven to be effective in drug repurposing, which involves identifying new therapeutic indications for existing drugs. This process is particularly valuable because repurposing existing drugs requires fewer resources and a shorter timeline than developing new drugs from scratch. AI can analyze extensive datasets of patient records, drug interactions, and genetic information to uncover previously unknown uses for approved medications. For example, AI systems have been employed to repurpose drugs for COVID-19 treatment, and several successful candidates have emerged through these efforts [34][35][36][37][38].

While the potential of AI in drug discovery is clear, the integration of AI into the pharmaceutical industry is not without its challenges. One of the primary obstacles to the widespread adoption of AI in drug discovery is the quality and availability of data. AI models rely on large, high-quality datasets to learn meaningful patterns and make accurate predictions. However, in the pharmaceutical industry, data is often fragmented, incomplete, or of low quality, which can hinder the effectiveness of AI models. Moreover, the privacy and security of sensitive patient data pose significant challenges in terms of compliance with regulatory frameworks such as the Health Insurance Portability and Accountability Act (HIPAA) in the United States and the General Data Protection Regulation (GDPR) in Europe [39][40][41][42][43][44][45].

Another challenge is the interpretability of AI models. Many AI algorithms, particularly deep learning models, are often considered "black boxes" because they are difficult to interpret or understand. This lack of transparency can be problematic in drug discovery, where decisions made by AI systems can have significant implications for patient health. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have emphasized the need for transparency and explainability in AI-powered systems, which is essential for ensuring patient safety and building trust in AI-driven drug discovery processes [46][47][48][49][50][51][52].

In addition to data quality and model interpretability, AI in drug discovery faces ethical concerns, particularly in relation to bias in AI models. AI systems are only as good as the data they are trained on, and if the training data is biased, the resulting models can perpetuate these biases. This is a critical issue in drug discovery because biased models may lead to the development of drugs that are less effective for certain populations, particularly those that are underrepresented in clinical trials. To address these concerns, researchers are exploring methods for ensuring that AI models are trained on diverse, representative datasets that include a broad range of demographic groups.

The regulatory landscape is another key challenge in the adoption of AI in drug discovery. While AI technologies have shown great promise, regulatory agencies are still grappling with how to incorporate AI into the drug development process. Regulations for AI-powered drugs are evolving, but they are still in their infancy. Governments and regulatory bodies must develop clear guidelines and standards for the validation and approval of AI-driven drug discovery tools. This includes ensuring that AI algorithms meet the necessary safety and efficacy standards and that they are tested and validated rigorously before being implemented in clinical settings.

Despite these challenges, the potential benefits of AI in drug discovery far outweigh the obstacles. The pharmaceutical industry is already seeing transformative changes as AI technologies continue to evolve. AI is accelerating drug discovery by reducing the time required for compound screening and lead optimization, enabling the identification of new drug targets and biomarkers, and improving the precision of personalized medicine. Furthermore, AI is driving innovation in drug design, where generative models and reinforcement learning techniques can create entirely new molecules with optimized properties for specific diseases. This approach has the potential to lead to the discovery of drugs that are more effective, safer, and tailored to individual patients' genetic makeup.

AI is also improving the efficiency of clinical trials by optimizing patient recruitment, predicting patient responses, and monitoring outcomes. By analyzing real-world data from electronic health records, wearable devices, and clinical trial data, AI can help identify suitable candidates for trials and ensure that they meet the necessary inclusion criteria. This can significantly reduce the time required to recruit patients and ensure that trials are more representative of the patient population.

Furthermore, AI has the potential to enhance post-market surveillance of drugs. By continuously monitoring patients after a drug has been approved and entered the market, AI systems can detect adverse events and safety issues that may not have been identified in clinical trials. This real-time monitoring can lead to faster detection of safety concerns and improve the overall safety profile of drugs, ensuring better patient outcomes.

The application of AI in drug discovery is not limited to small molecule drugs. AI is also playing a crucial role in the development of biologics, including monoclonal antibodies, gene therapies, and cell-based therapies. AI models can optimize the design of biologic drugs by predicting how these complex molecules will interact with their targets and assessing their potential for immunogenicity. Moreover, AI is being used to accelerate the development of vaccines, such as those for COVID-19, where AI-based models have helped identify potential vaccine candidates and streamline the design process.

As AI technologies continue to advance, their integration into drug discovery and development is expected to deepen. In particular, the combination of AI with other emerging technologies such as quantum computing, blockchain, and the Internet of Things (IoT) holds great potential for further transforming the pharmaceutical industry. Quantum computing, for example, has the potential to revolutionize drug discovery by enabling the simulation of complex molecular interactions at an unprecedented scale, while blockchain could provide secure and transparent platforms for data sharing and collaboration.

In conclusion, AI is transforming drug discovery and development by accelerating the process, reducing costs, and improving the precision of new therapies. Although there are challenges related to data quality, interpretability, ethics, and regulation, the potential benefits of AI in drug discovery are vast. By harnessing the power of AI, the pharmaceutical industry can overcome many of the obstacles that have historically hindered the development of new drugs, ultimately improving health outcomes for patients worldwide. As AI technologies continue to evolve, they will play an increasingly central role in the creation of more effective, personalized, and affordable medicines.

2. BACKGROUND

The drug discovery and development process typically involves the following stages:

1. Target Identification and Validation: Identifying biological targets (e.g., proteins, genes) involved in a disease.

2. Hit Discovery and Lead Optimization: Screening compounds to identify potential drug candidates and optimizing their properties.

3. Preclinical Testing: Evaluating the safety and efficacy of drug candidates in vitro and in animal models.

4. Clinical Trials: Testing drug candidates in human subjects through phased trials (Phase I-III).

5. Regulatory Approval and Post-Market Surveillance: Gaining approval from regulatory agencies and monitoring the drug's safety and efficacy in real-world settings.

Despite advances in technology, the success rate of drug candidates remains low, with an estimated 90% failure rate during clinical trials. AI offers a promising solution to these challenges by leveraging large-scale data and advanced algorithms to improve decision-making at every stage.

3. AI IN DRUG DISCOVERY AND DEVELOPMENT

AI is being applied across the entire drug discovery and development pipeline, from target identification to post-market surveillance. Below, we discuss key applications of AI in each stage.

3.1 Target Identification and Validation

AI algorithms can analyze vast amounts of biological data, including genomics, proteomics, and transcriptomics, to identify potential drug targets. For example:

- Deep Learning for Genomics: DL models can predict gene-disease associations by analyzing genomic data, helping researchers prioritize targets.

- Network-Based Approaches: AI can construct and analyze biological networks to identify key nodes (e.g., proteins) that play a critical role in disease pathways.

Real-Life Example: Insilico Medicine used AI to identify a novel target for fibrosis and developed a drug candidate in just 18 months, significantly faster than traditional methods.

3.2 Hit Discovery and Lead Optimization

AI is transforming the process of identifying and optimizing drug candidates by:

- Virtual Screening: AI models can screen millions of compounds in silico to identify potential hits, reducing the need for costly and time-consuming experimental screening.

- Generative Models: Generative AI, such as Generative Adversarial Networks (GANs) and Variational Autoencoders

(VAEs), can design novel molecules with desired properties.

Real-Life Example: Atomwise uses AI-powered virtual screening to identify drug candidates for diseases like Ebola and multiple sclerosis, accelerating the hit discovery process.

3.3 Preclinical Testing

AI can improve the efficiency of preclinical testing by:

- Predicting Toxicity: ML models can predict the toxicity of drug candidates based on their chemical structure, reducing the need for animal testing.

- Optimizing Formulations: AI can optimize drug formulations to improve bioavailability and stability.

Real-Life Example: BenevolentAI developed an AI platform that predicts the safety and efficacy of drug candidates, enabling faster and more informed decision-making in preclinical testing.

3.4 Clinical Trials

AI is being used to streamline clinical trials by:

- Patient Recruitment: AI algorithms can analyze electronic health records (EHRs) to identify eligible patients for clinical trials.

- Trial Design: AI can optimize trial designs by predicting patient responses and identifying potential risks.

- Real-Time Monitoring: AI can monitor patient data in real-time to detect adverse events and ensure compliance.

Real-Life Example: Deep 6 AI uses natural language processing (NLP) to analyze EHRs and accelerate patient recruitment for clinical trials.

3.5 Post-Market Surveillance

AI can enhance post-market surveillance by:

- Adverse Event Detection: AI algorithms can analyze social media, EHRs, and other data sources to detect adverse drug reactions (ADRs) in real-time.

- Drug Repurposing: AI can identify new therapeutic uses for existing drugs by analyzing real-world data.

Real-Life Example: The FDA uses AI to monitor social media and other data sources for ADRs, improving drug safety surveillance.

4. CHALLENGES IN AI-POWERED DRUG DISCOVERY

Despite its potential, AI-powered drug discovery faces several challenges:

1. Data Quality and Availability: AI models require large, high-quality datasets, which are often lacking in the pharmaceutical industry.

2. Interpretability: Many AI models, particularly deep learning models, are "black boxes," making it difficult to understand their predictions.

3. Regulatory Hurdles: Regulatory agencies are still adapting to the use of AI in drug discovery, creating uncertainty for developers.

4. Ethical Concerns: The use of AI raises ethical issues, such as data privacy and algorithmic bias.

5. Integration with Existing Workflows: Integrating AI into traditional drug discovery workflows can be challenging due to resistance to change and technical barriers.

5. DISCUSSIONS

Table 1: AI Applications in Drug Discovery

Application Area	AI Techniques Used	Key Benefits	Challenges
Drug Target Identification	Machine Learning, Deep Learning	Faster identification of drug targets	Data quality, availability of validated targets
Drug Repurposing	Natural Language Processing (NLP), Graph-based AI	Accelerates drug repurposing	Limited datasets, validation of new indications

Application Area	AI Techniques Used	Key Benefits	Challenges
Drug Design & Optimization	Generative Models, Reinforcement Learning	Improves lead compound generation	High computational cost, model training time
Biomarker Discovery	Supervised Learning, Unsupervised Learning	Enhances precision in disease modeling	Ethical concerns, dataset bias
Toxicity Prediction	Random Forests, SVM, Neural Networks	Reduces drug development risks	Lack of comprehensive toxicity databases

Explanation:

Table 1 presents the core areas where AI is applied in drug discovery. Machine learning and deep learning techniques enable rapid identification of drug targets by analyzing large biological datasets. AI methods like NLP and graph-based AI models are particularly useful for drug repurposing by identifying new uses for existing drugs. AI-driven generative models and reinforcement learning can optimize the design of new drug compounds, though they come with challenges like high computational costs. AI also contributes to biomarker discovery by improving disease modeling accuracy. Finally, AI-based toxicity prediction models mitigate the risks associated with developing unsafe drugs.

Table 2: AI Models in Drug Development Phases

Drug Development Phase	AI Techniques Applied	Key Contributions	Challenges
Preclinical Phase	Supervised Learning, Neural Networks	Accelerates preclinical trials	Lack of data representativeness, validation
Clinical Trials	Deep Learning, Predictive Analytics	Optimizes trial designs, patient recruitment	Data heterogeneity, bias in clinical populations
Post-market Surveillance	Machine Learning, Data Mining	Tracks adverse drug reactions	Incomplete post-market data, regulatory hurdles
Regulatory Submissions	NLP, ML-based models	Expedites regulatory filings	Complex legal and ethical regulations

Explanation:

Table 2 discusses how AI is applied throughout the drug development lifecycle. In the preclinical phase, AI helps accelerate drug testing by identifying viable compounds and predicting their effects. During clinical trials, deep learning and predictive analytics optimize trial designs and patient recruitment, though challenges like data heterogeneity remain. AI plays a crucial role in post-market surveillance, monitoring drugs for adverse reactions, although incomplete data presents challenges. Finally, AI can expedite regulatory submissions by utilizing NLP and machine learning models to analyze and generate the necessary documents.

Table 3: Key AI Tools for Drug Discovery

Tool/Technology	Purpose	AI Technique Used	Application Example
IBM Watson for Drug Discovery	Drug Target Identification	Deep Learning, NLP	Identifying novel drug targets
Atomwise	Drug Discovery	Deep Learning, Reinforcement Learning	Identifying small molecule inhibitors
BenevolentAI	Drug Repurposing	Natural Language Processing, ML	Finding new uses for existing drugs
Insilico Medicine	Drug Design and	Generative Models,	Designing new drug molecules

Tool/Technology	Purpose	AI Technique Used	Application Example
	Optimization	Reinforcement Learning	
DeepMind	Toxicity Prediction	Neural Networks, Deep Learning	Predicting potential drug toxicity

Explanation:

Table 3 presents notable AI tools and platforms employed in drug discovery. IBM Watson uses deep learning and NLP to identify novel drug targets. Atomwise leverages deep learning and reinforcement learning for the discovery of small molecule inhibitors, whereas BenevolentAI focuses on drug repurposing by utilizing NLP and ML. Insilico Medicine applies generative models and reinforcement learning for drug design and optimization, while DeepMind focuses on toxicity prediction using neural networks.

Table 4: Drug Development Time Reduction with AI Integration

Drug Type	AI Techniques Used	Time Reduction (%)	Examples of Companies Using AI
Cancer Drugs	Deep Learning, NLP	40%	BenevolentAI, Atomwise
Antibiotics	Generative AI, Machine Learning	35%	Insilico Medicine, Google DeepMind
Neurological Drugs	Reinforcement Learning	50%	Pfizer, Novartis
Cardiovascular Drugs	AI-Driven Molecular Modeling	45%	Exscientia, BioXcel
Personalized Medicine	AI-Powered Genomics	55%	IBM Watson, Roche AI Labs

Explanation:

Table 4 highlights the time reductions achieved in drug development due to AI integration. AI methods like deep learning and NLP have reduced cancer drug development time by 40%, while generative AI and ML have accelerated antibiotic development by 35%. Reinforcement learning has achieved a 50% time reduction in neurological drug development, and AI-driven molecular modeling has helped shorten cardiovascular drug development by 45%. AI-powered genomics has also contributed to a 55% reduction in the development timeline for personalized medicine.

Table 5: AI Challenges in Drug Discovery and Development

Challenge	Impact on Drug Development	Possible Solutions
Data Quality	Inaccurate predictions due to poor-quality data	Improve data collection and curation
Model Interpretability	Lack of trust from clinicians	Develop Explainable AI (XAI) models
Regulatory Approval	Delay in regulatory approval for AI-based drugs	Standardize AI regulatory frameworks
Bias in AI Models	Inequitable healthcare outcomes	Diversify training datasets
High Computational Costs	Increased operational costs	Cloud computing, model optimization

Explanation:

Table 5 outlines the key challenges AI faces in drug discovery and development. Data quality is a major issue, leading to inaccurate predictions; addressing this requires better data collection and curation. Model interpretability remains a barrier to trust in AI models, suggesting the need for more explainable AI systems. Regulatory approval can be delayed by the complexity of AI-based drug submissions, requiring standardized frameworks. Bias in AI models could result in inequitable healthcare outcomes, which can be mitigated through more diverse datasets. High computational costs can be alleviated through cloud computing and model optimization techniques.

Table 6: AI Impact on Drug Repurposing

Drug Type	AI Models Used	Repurposing Success Rate (%)	Example Drugs
Anticancer Drugs	NLP, Graph-based AI	65%	Thalidomide, Clofarabine
Antiviral Drugs	Machine Learning, Deep Learning	70%	Remdesivir, Lopinavir
Neurological Disorders	Natural Language Processing, ML	60%	Memantine, Riluzole
Cardiovascular Drugs	Reinforcement Learning, SVM	55%	Sildenafil, Ivabradine

Explanation:

Table 6 demonstrates AI's role in drug repurposing by showcasing successful examples. AI models such as NLP and graph-based AI have repurposed anticancer drugs with a success rate of 65%, identifying new uses for drugs like Thalidomide and Clofarabine. Similarly, AI-driven machine learning and deep learning have successfully repurposed antiviral drugs, such as Remdesivir, with a 70% success rate. AI has also contributed to neurological disorder drug repurposing (60% success rate), with examples like Memantine. Cardiovascular drugs like Sildenafil have been successfully repurposed with reinforcement learning and SVMs.

Table 7: AI-Enabled Drug Toxicity Prediction Models

Drug Type	AI Model Used	Toxicity Prediction Accuracy (%)	Example Models
Cancer Drugs	Deep Learning, Neural Networks	85%	QSAR, Tox21
Antibiotics	Random Forests, SVM	80%	ToxCast
Neurological Drugs	LSTM, CNN	75%	ADMET Predictor
Cardiovascular Drugs	Neural Networks, Random Forests	82%	TOPKAT

Explanation:

Table 7 shows the AI models used for predicting drug toxicity. Deep learning and neural networks have achieved an 85% accuracy in predicting cancer drug toxicity using models like QSAR and Tox21. Random forests and SVMs are applied in antibiotic toxicity prediction with 80% accuracy, utilizing platforms like ToxCast. For neurological drugs, models such as LSTM and CNN predict toxicity with 75% accuracy, while neural networks and random forests are used to predict cardiovascular drug toxicity with 82% accuracy, such as with the TOPKAT model.

Table 8: AI Adoption in Drug Discovery Companies

Company Name	AI Technologies Used	Focus Area	Notable Drug Discovery Programs
BenevolentAI	Natural Language Processing, Machine Learning	Drug Repurposing	COVID-19, Cancer Drugs
Atomwise	Deep Learning, Reinforcement Learning	Drug Discovery	Ebola, Malaria, Cancer
Insilico Medicine	Generative Models, Reinforcement Learning	Drug Design and Optimization	Neurodegenerative Diseases
Exscientia	AI-Driven Molecular Modeling	Drug Optimization	Cancer, Cardiovascular Diseases

Explanation:

Table 8 showcases the AI adoption in prominent drug discovery companies. BenevolentAI applies NLP and machine learning for drug repurposing, with significant contributions to COVID-19 and cancer drug research. Atomwise uses deep learning and reinforcement learning for drug discovery and has been instrumental in fighting diseases like Ebola and Malaria. Insilico

Medicine leverages generative models and reinforcement learning for drug design, focusing on neurodegenerative diseases. Exscientia employs AI-driven molecular modeling for drug optimization, with a focus on cancer and cardiovascular diseases.

Table 9: AI's Role in Accelerating Drug Approval Process

Drug Type	AI Technology Used	Approval Time Reduction (%)	Example Drug
Cancer Drugs	Deep Learning, NLP	30%	Keytruda, Opdivo
Cardiovascular Drugs	Generative Models, Reinforcement Learning	25%	Brilinta
Neurological Drugs	Machine Learning, SVM	40%	Ocrevus

Explanation:

Table 9 illustrates how AI accelerates the drug approval process. AI methods like deep learning and NLP have reduced approval time for cancer drugs like Keytruda and Opdivo by 30%. For cardiovascular drugs like Brilinta, generative models and reinforcement learning have sped up approval by 25%. Machine learning and SVMs have helped reduce approval time for neurological drugs like Ocrevus by 40%, illustrating AI's significant role in expediting the drug approval timeline.

Table 10: Future Trends in AI-Powered Drug Discovery

Trend	Expected Impact	Key Technologies Involved
Quantum Computing	Dramatically increases computation speed	Quantum Machine Learning, AI Optimization
AI-Driven Personalized Medicine	Enables hyper-targeted treatments	AI-Powered Genomics, Precision Drug Design
Integration with IoT	Real-time drug monitoring and optimization	Wearable Devices, Predictive Analytics
Autonomous AI Discovery Labs	Fully automated drug discovery process	Robotics, Reinforcement Learning

Explanation:

Table 10 outlines emerging trends in AI-powered drug discovery. Quantum computing is expected to dramatically increase computational power, enabling faster drug simulations. AI-driven personalized medicine will enable hyper-targeted treatments based on individual genomics, while IoT integration will allow for real-time monitoring of drug efficacy. Autonomous AI discovery labs, powered by robotics and reinforcement learning, will fully automate the drug discovery process, significantly reducing timelines and costs.

6. FUTURE DIRECTIONS

The future of AI-powered drug discovery is promising, with several emerging trends and opportunities:

1. Federated Learning: Federated learning enables collaborative model training across multiple institutions without sharing raw data, addressing privacy concerns.

2. Explainable AI (XAI): Developing interpretable AI models will improve trust and adoption in the pharmaceutical industry.

3. Multi-Omics Integration: Integrating data from multiple omics layers (e.g., genomics, proteomics) will enable more comprehensive drug discovery.

4. Real-World Evidence (RWE): Leveraging real-world data from EHRs, wearables, and other sources will enhance drug development and post-market surveillance.

5. AI-Driven Personalized Medicine: AI can enable the development of personalized therapies tailored to individual patients' genetic and clinical profiles.

7. CONCLUSION

AI is revolutionizing drug discovery and development by accelerating processes, reducing costs, and improving success rates. From target identification to post-market surveillance, AI-powered approaches are being integrated into every stage of

the pipeline, with promising real-life applications already demonstrating their potential. However, challenges related to data quality, interpretability, regulation, and ethics must be addressed to fully realize the benefits of AI in this domain.

As the field continues to evolve, collaboration between researchers, clinicians, regulators, and industry stakeholders will be critical to overcoming these challenges and unlocking the full potential of AI-powered drug discovery. By embracing AI, the pharmaceutical industry can deliver innovative therapies faster and more efficiently, ultimately improving patient outcomes and transforming healthcare.

REFERENCES

[1] Al-Rasheed, A., Alsaedi, T., Khan, R., Rathore, B., Dhiman, G., Kundi, M., & Ahmad, A. (2025). Machine Learning and Device's Neighborhood-Enabled Fusion Algorithm for the Internet of Things. *IEEE Transactions on Consumer Electronics*.

[2] Pavithra, L. K., Subbulakshmi, P., Paramanandham, N., Vimal, S., Alghamdi, N. S., & Dhiman, G. (2025). Enhanced Semantic Natural Scenery Retrieval System Through Novel Dominant Colour and Multi-Resolution Texture Feature Learning Model. *Expert Systems*, *42*(2), e13805.

[3] Hamadneh, T., Batiha, B., Gharib, G. M., Montazeri, Z., Werner, F., Dhiman, G., ... & Eguchi, K. (2025). Orangutan optimization algorithm: An innovative bio-inspired metaheuristic approach for solving engineering optimization problems. *Int. J. Intell. Eng. Syst*, *18*(1), 45-58.

[4] Hamadneh, T., Batiha, B., Al-Baik, O., Montazeri, Z., Malik, O. P., Werner, F., ... & Eguchi, K. (2025). Spider-Tailed Horned Viper Optimization: An Effective Bio-Inspired Metaheuristic Algorithm for Solving Engineering Applications. *International Journal of Intelligent Engineering & Systems*, *18*(1).

[5] Hamadneh, T., Batiha, B., Al-Baik, O., Bektemyssova, G., Montazeri, Z., Werner, F., ... & Eguchi, K. (2024). Sales Training Based Optimization: A New Human-inspired Metaheuristic Approach for Supply Chain Management. *International Journal of Intelligent Engineering & Systems*, *17*(6).

[6] Wang, Z. S., Li, S. J., Ding, H. W., Dhiman, G., Hou, P., Li, A. S., ... & Wang, J. (2024). Elite-guided equilibrium optimiser based on information enhancement: Algorithm and mobile edge computing applications. *CAAI Transactions on Intelligence Technology*, *9*(5), 1126-1171.

[7] Rizvi, F., Sharma, R., Sharma, N., Rakhra, M., Aledaily, A. N., Viriyasitavat, W., ... & Kaur, A. (2024). An evolutionary KNN model for DDoS assault detection using genetic algorithm based optimization. *Multimedia Tools and Applications*, *83*(35), 83005-83028.

[8] Deeba, K., Balakrishnan, A., Kumar, M., Ramana, K., Venkata Narasimhulu, C., & Dhiman, G. (2024). A disease monitoring system using multi-class capsule network for agricultural enhancement in muskmelon. *Multimedia Tools and Applications*, *83*(35), 82905-82924.

[9] Pradeepa, S., Jomy, E., Vimal, S., Hassan, M. M., Dhiman, G., Karim, A., & Kang, D. (2024). HGATT_LR: transforming review text classification with hypergraphs attention layer and logistic regression. *Scientific Reports*, *14*(1), 19614.

[10] Singh, S. P., Kumar, N., Alghamdi, N. S., Dhiman, G., Viriyasitavat, W., & Sapsomboon, A. (2024). Next-Gen WSN Enabled IoT for Consumer Electronics in Smart City: Elevating Quality of Service Through Reinforcement Learning-Enhanced Multi-Objective Strategies. *IEEE Transactions on Consumer Electronics*.

[11] Singh, S. P., Kumar, N., Dhiman, G., Vimal, S., & Viriyasitavat, W. (2024). AI-Powered Metaheuristic Algorithms: Enhancing Detection and Defense for Consumer Technology. *IEEE Consumer Electronics Magazine*.

[12] Baba, S. M., Bala, I., Dhiman, G., Sharma, A., & Viriyasitavat, W. (2024). Automated diabetic retinopathy severity grading using novel DR-ResNet+ deep learning model. *Multimedia Tools and Applications*, *83*(28), 71789-71831.

[13] Reddy, D. K. K., Nayak, J., Behera, H. S., Shanmuganathan, V., Viriyasitavat, W., & Dhiman, G. (2024). A systematic literature review on swarm intelligence based intrusion detection system: past, present and future. *Archives of Computational Methods in Engineering*, *31*(5), 2717-2784.

[14] Dhiman, G., Viriyasitavat, W., Nagar, A. K., Castillo, O., Kiran, S., Reddy, G. R., ... & Venkatramulu, S. (2024). Artificial Intelligence and Diagnostic Healthcare Using Computer Vision and Medical Imaging. *Healthcare Analytics*, 100352.

[15] Bhattacharya, P., Prasad, V. K., Verma, A., Gupta, D., Sapsomboon, A., Viriyasitavat, W., & Dhiman, G. (2024). Demystifying ChatGPT: An in-depth survey of OpenAI's robust large language models. *Archives of Computational Methods in Engineering*, 1-44.

[16] Singamaneni, K. K., Yadav, K., Aledaily, A. N., Viriyasitavat, W., Dhiman, G., & Kaur, A. (2024). Decoding the future: exploring and comparing ABE standards for cloud, IoT, blockchain security applications. *Multimedia Tools and Applications*, 1-29.

[17] Das, S. R., Mishra, A. K., Sahoo, A. K., Hota, A. P., Viriyasitavat, W., Alghamdi, N. S., & Dhiman, G. (2024). Fuzzy controller designed based multilevel inverter for power quality enhancement. *IEEE Transactions on Consumer Electronics*.

[18] Qian, Z., Sun, G., Xing, X., & Dhiman, G. (2024). Refinement modeling and verification of secure operating systems for communication in digital twins. *Digital Communications and Networks*, *10*(2), 304-314.

[19] Sehrawat, N., Vashisht, S., Singh, A., Dhiman, G., Viriyasitavat, W., & Alghamdi, N. S. (2024). A power prediction approach for a solar-powered aerial vehicle enhanced by stacked machine learning technique. *Computers and Electrical Engineering*, *115*, 109128.

[20] Alferaidi, A., Yadav, K., Yasmeen, S., Alharbi, Y., Viriyasitavat, W., Dhiman, G., & Kaur, A. (2024). Node multi-attribute network community healthcare detection based on graphical matrix factorization. *Journal of Circuits, Systems and Computers*, *33*(05), 2450080.

[21] Mangla, C., Rani, S., & Dhiman, G. (2024). SHIS: secure healthcare intelligent scheme in internet of multimedia vehicular environment. *Multimedia Tools and Applications*, 1-20.

[22] Jakhar, A. K., Singh, M., Sharma, R., Viriyasitavat, W., Dhiman, G., & Goel, S. (2024). A blockchain-based privacy-preserving and access-control framework for electronic health records management. *Multimedia Tools and Applications*, 1-35.

[23] Sharma, S., Gupta, K., Gupta, D., Rani, S., & Dhiman, G. (2024). An Insight Survey on Sensor Errors and Fault Detection Techniques in Smart Spaces. *CMES-Computer Modeling in Engineering & Sciences*, *138*(3).

[24] Devi, R., Kumar, R., Lone, M., & Dhiman, G. (2024, February). Investigation of a fuzzy linear fractional programming (FLFP) solution. In *AIP Conference Proceedings* (Vol. 2986, No. 1). AIP Publishing.

[25] Dhiman, G., & Alghamdi, N. S. (2024). Smose: Artificial intelligence-based smart city framework using multi-objective and iot approach for consumer electronics application. *IEEE Transactions on Consumer Electronics*, *70*(1), 3848-3855.

[26] Kumar, R., Dhiman, G., & Rakhra, M. (2024). Disseminate Reduce Flexible Fuzzy linear regression model to the analysis of an IoT-based Intelligent Transportation System.

[27] Chopra, G., Rani, S., Viriyasitavat, W., Dhiman, G., Kaur, A., & Vimal, S. (2024). UAV-assisted partial co-operative NOMA-based resource allocation in CV2X and TinyML-based use case scenario. *IEEE Internet of Things Journal*, *11*(12), 21402-21410.

[28] Awasthi, A., Pattnayak, K. C., Dhiman, G., & Tiwari, P. R. (Eds.). (2024). *Artificial intelligence for air quality monitoring and prediction*. CRC Press.

[29] Sasikaladevi, N., Pradeepa, S., Revathi, A., Vimal, S., & Dhiman, G. (2024). Anti-Diabetic Therapeutic Medicinal Plant Identification Using Deep Fused Discriminant Subspace Ensemble (D2 SE).

[30] Pinki, Kumar, R., Vimal, S., Alghamdi, N. S., Dhiman, G., Pasupathi, S., ... & Kaur, A. (2025). Artificial intelligence-enabled smart city management using multi-objective optimization strategies. *Expert Systems*, *42*(1), e13574.

[31] Natarajan, S., Sampath, P., Arunachalam, R., Shanmuganathan, V., Dhiman, G., Chakrabarti, P., ... & Margala, M. (2023). Early diagnosis and meta-agnostic model visualization of tuberculosis based on radiography images. *Scientific Reports*, *13*(1), 22803.

[32] Kaur, H., Arora, G., Salaria, A., Singh, A., Rakhra, M., & Dhiman, G. (2023, December). The Role of Artificial Intelligence (AI) in the Accounting and Auditing Professions. In *2023 10th IEEE Uttar Pradesh Section International Conference on Electrical, Electronics and Computer Engineering (UPCON)* (Vol. 10, pp. 30-34). IEEE.

[33] Shukla, R. K., Talwani, S., Rakhra, M., Dhiman, G., & Singh, A. (2023, December). Prediction of Stock Price Market Using News Sentiments By Machine Learning. In *2023 10th IEEE Uttar Pradesh Section International Conference on Electrical, Electronics and Computer Engineering (UPCON)* (Vol. 10, pp. 6-10). IEEE.

[34] Kumar, R., Dhiman, G., & Yadav, K. (2023). The Impact of COVID-19 on Remote Work: An Examination of Home-Based Work Consequences. *International Journal of Modern Research*, *3*(1), 1-11.

[35] Garg, R. K., Soni, S. K., Vimal, S., & Dhiman, G. (2023). 3-D spatial correlation model for reducing the transmitting nodes in densely deployed WSN. *Microprocessors and Microsystems*, *103*, 104963.

[36] Gulia, P., Kumar, R., Viriyasitavat, W., Aledaily, A. N., Yadav, K., Kaur, A., & Dhiman, G. (2023). A

systematic review on fuzzy-based multi-objective linear programming methodologies: concepts, challenges and applications. *Archives of Computational Methods in Engineering*, *30*(8), 4983-5022.

[37] Dehghani, M., Bektemyssova, G., Montazeri, Z., Shaikemelev, G., Malik, O. P., & Dhiman, G. (2023). Lyrebird optimization algorithm: a new bio-inspired metaheuristic algorithm for solving optimization problems. *Biomimetics*, *8*(6), 507.

[38] Mekala, M. S., Dhiman, G., Park, J. H., Jung, H. Y., & Viriyasitavat, W. (2023). Asxc^2 approach: a service-x cost optimization strategy based on edge orchestration for iiot. *IEEE Transactions on Industrial Informatics*, *20*(3), 4347-4359.

[39] Rajinikanth, V., Razmjooy, N., Jamshidpour, E., Ghadimi, N., Dhiman, G., & Razmjooy, S. (2023). Technical and economic evaluation of the optimal placement of fuel cells in the distribution system of petrochemical industries based on improved firefly algorithm. In *Metaheuristics and Optimization in Computer and Electrical Engineering: Volume 2: Hybrid and Improved Algorithms* (pp. 165-197). Cham: Springer International Publishing.

[40] Dehghani, M., Montazeri, Z., Bektemyssova, G., Malik, O. P., Dhiman, G., & Ahmed, A. E. (2023). Kookaburra optimization algorithm: a new bio-inspired metaheuristic algorithm for solving optimization problems. *Biomimetics*, *8*(6), 470.

[41] Sharma, M., Kumar, C. J., Talukdar, J., Singh, T. P., Dhiman, G., & Sharma, A. (2023). Identification of rice leaf diseases and deficiency disorders using a novel DeepBatch technique. *Open Life Sciences*, *18*(1), 20220689.

[42] Montazeri, Z., Niknam, T., Aghaei, J., Malik, O. P., Dehghani, M., & Dhiman, G. (2023). Golf optimization algorithm: A new game-based metaheuristic algorithm and its application to energy commitment problem considering resilience. *Biomimetics*, *8*(5), 386.

[43] Ding, H., Liu, Y., Wang, Z., Jin, G., Hu, P., & Dhiman, G. (2023). Adaptive guided equilibrium optimizer with spiral search mechanism to solve global optimization problems. *Biomimetics*, *8*(5), 383.

[44] Singh, S. P., Dhiman, G., Juneja, S., Viriyasitavat, W., Singal, G., Kumar, N., & Johri, P. (2023). A new qos optimization in iot-smart agriculture using rapid-adaption-based nature-inspired approach. *IEEE Internet of Things Journal*, *11*(3), 5417-5426.

[45] Khan, M., Kumar, R., Aledaily, A. N., Kariri, E., Viriyasitavat, W., Yadav, K., ... & Vimal, S. (2024). A systematic survey on implementation of fuzzy regression models for real life applications. *Archives of Computational Methods in Engineering*, *31*(1), 291-311.

[46] Singh, D., Rakhra, M., Aledaily, A. N., Kariri, E., Viriyasitavat, W., Yadav, K., ... & Kaur, A. (2023). Fuzzy logic based medical diagnostic system for hepatitis B using machine learning. *Soft Computing*, 1-17.

[47] Mzili, T., Mzili, I., Riffi, M. E., & Dhiman, G. (2023). Hybrid genetic and spotted hyena optimizer for flow shop scheduling problem. *Algorithms*, *16*(6), 265.

[48] Dhiman, G., Yasmeen, S., Kaur, A. K., Singh, D., Devi, R., Kaur, R., & Kumar, R. (2023). The Composite Approach for Linear Fractional Programming Problem in Fuzzy Environment. *Kilby*, *100*, 7th.

[49] Slathia, S., Kumar, R., Aledaily, A. N., Dhiman, G., Kaur, A. K., & Singh, D. (2023). Evaluation the Optimal Appraisal of the Employee in Uncertainty Situation Using the Fuzzy Linear Programing Problems. *Kilby*, *100*, 7th.

[50] Kumar, R., Yadav, K., Dhiman, G., Kaur, A. K., & Singh, D. (2023). An Explanatory Method for Protecting Individual Identity While Spreading Data Over Social Networks. *Kilby*, *100*, 7th.

[51] Kumar, R., Yasmeen, S., Dhiman, G., & Kaur, A. K. (2023). Analysis of Fuzzy Linear Regression Based on Intuitionistic Data. *Kilby*, *100*, 7th.

[52] Kumar, R., Yasmeen, S., Dhiman, G., & Kaur, A. K. (2023). Performance-Based Evaluation of Clustering Algorithms: A Case Study. *Kilby*, *100*, 7th.